Back to search

Article

A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

2022-07-17

Abstract excerpt

<h4>Background</h4> Limited treatment options exist for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a novel oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor. While phase 2 studies of ensitrelvir have demonstrated promising results in treating mild-to-moderate COVID-19, evaluation o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
19f800df-3377-5827-b008-77d777006606
DOI
10.1101/2022.07.15.22277670
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)DOI 10.1101/2022.07.15.22277670
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical TrialSemantic proximity
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Semantic proximity
Ensitrelvir treatment–emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trialSemantic proximity
Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 TrialsSemantic proximity
Ensitrelvir Fumaric Acid in Patients with SARS-CoV-2: A Retrospective Chart ReviewSemantic proximity
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoSemantic proximity
Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity
External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European populationSemantic proximity
Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity
SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity
A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study)Semantic proximity
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Semantic proximity
Select a neighboring publication to make it the new centre.